옵션 체인은 다양한 행사가격과 만기일에 대한 T2 Biosystems의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 T2 Biosystems에 대한 시장 심리를 평가합니다..

T2 Biosystems (OTC:TTOO) 주식, 옵션 체인

T2 Biosystems

T2 Biosystems Inc is a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes. It is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. The company's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the proprietary T2 Magnetic Resonance technology.

T2 Biosystems Inc

<h3>Gainers</h3>
<ul>
<li>Lipella Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) stock moved upwards by 49.5% to $4.56 during Tuesday's pre-market session. The market value of their outstanding shares is at $5.5 million. </li>
<li>IN8bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) shares increased by 49.46% to $0.4. The company's market cap stands at $29.2 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) stock rose 38.58% to $0.21. The company's market cap stands at $7.1 million. </li>
<li>Firefly Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIFF#NASDAQ">AIFF</a>) stock rose 38.06% to $4.28. The market value of their outstanding shares is at $34.2 million. </li>
<li>Travere Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>) stock rose 16.35% to $24.55. The company's market cap stands at $2.1 billion. </li>
<li>Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) shares increased by 13.06% to $5.54. The company's market cap stands at $118.1 million. As per the press release, Q1 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>T2 Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>) shares declined by 43.4% to $0.11 during Tuesday's pre-market session. The market value of their outstanding shares is at $3.0 million. </li>
<li>Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) shares fell 29.25% to $3.29. The company's market cap stands at $148.2 million. </li>
<li>Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) stock declined by 26.7% to $0.26. The company's market cap stands at $4.4 million. </li>
<li>vTv Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) shares declined by 18.97% to $15.0. The market value of their outstanding shares is at $39.1 million. </li>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) stock fell 17.54% to $1.88. The company's market cap stands at $4.2 million. </li>
<li>Hyperfine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) stock decreased by 16.77% to $1.39. The company's market cap stands at $101.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AIFF

ENTA

HYPR

INAB

LIPO

LIXT

OCEA

THRD

TTOO

TVTX

VTVT

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

News

Guidance

T2 Biosystems Announces Prelim. Financial Results; Sees Q4 Revenues Of $2.3M And 2024 Revenues Of $8.3M

The multiple instrument sale demonstrates commercial expansion to enable increased utilization of the T2Bacteria&#xAE; Panel, the T2Candida&#xAE; Panel, and the T2Resistance&#xAE; Panel. The target hospitals for the new instruments include:
<ul>
<li>Selling a second T2Dx Instrument to a major reference hospital to expand "same store" sales;</li>
<li>Selling the first T2Dx Instrument to a hospital in a country for initial market penetration; and</li>
<li>Selling two T2Dx Instruments to hospitals in countries that already utilize T2 Biosystems' products. &nbsp;</li>
</ul>

Asset Sales

T2 Biosystems Sells Four T2Dx Instruments To Existing European Distributor; Amount Not Disclosed

Contracts

T2 Biosystems Announced That Its Multi-Year Capital Equipment Supplier Agreement With Vizient Has Been Extended Through March 31, 2026

Biotech

General

T2 Biosystems To License Proprietary Technology For Direct-From-Whole-Blood Sepsis Pathogen Detection, Aiming To Generate Non-Dilutive Capital, Create Royalty Revenue Streams, And Broaden Adoption Of FDA-Cleared Diagnostics Powered By T2MR Detection And Adaptable Sample Processing Technology

T2 Biosystems shares are trading lower after the company reported worse-than-expected Q3 revenue results.

T2 Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>) .

T2 Biosystems Expects Q4 2024 sepsis product revenue to be $2.5M to $3.5M.

T2 Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(0.64) by 10.94 percent. The company reported quarterly sales of $1.985 million which missed the analyst consensus estimate of $2.800 million by 29.11 percent. This is a 34.85 percent increase over sales of $1.472 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

T2 Biosystems Q3 2024 GAAP EPS $(0.57) Beats $(0.64) Estimate, Sales $1.985M Miss $2.800M Estimate

AFMD

AGAE

AIRI

AKYA

AMAT

AQMS

AREC

ASND

ASTS

AZUL

BENF

BILI

BIOR

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BKTI

BKYI

BLUE

BNAI

BNZI

BRAG

BTAI

CASI

CELC

CINT

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

CNVS

CRIS

CWCO

DARE

DBGI

DESP

DFLI

DLPN

DMRC

DNMR

DPRO

DTST

EAST

EFXT

ELUT

EWCZ

FLNT

FTLF

GAMB

GAME

GCTS

GDEV

GLOB

HYLN

IMCC

INKT

INTR

ITRM

IVVD

IZEA

LCTX

LIQT

LOCL

LUNR

MITQ

MOVE

MSGM

MUFG

NICE

NOMD

NTES

OCFT

OCUL

OKLO

ONEW

ORGN

PDSB

PHGE

POCI

POST

Earnings Scheduled For November 14, 2024

T2 Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>) is set to give its latest quarterly earnings report on Thursday, 2024-11-14. Here's what investors need to know before the announcement.
Analysts estimate that T2 Biosystems will report an earnings per share (EPS) of $-0.64. 
The market awaits T2 Biosystems's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.31, leading to a 3.16% increase in the share price on the subsequent day.
Here's a look at T2 Biosystems's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.97</td>
<td>-2.27</td>
<td>-2.22</td>
<td>-4</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.66</td>
<td>-2.66</td>
<td>-2.08</td>
<td>-3.45</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>-11.0%</td>
<td>-1.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731513715_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of T2 Biosystems were trading at $0.524 as of November 12. Over the last 52-week period, shares are down 87.44%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/TTOO/earnings">To track all earnings releases for T2 Biosystems visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights Ahead: T2 Biosystems's Quarterly Earnings

T2 Biosystems And Prxcision Announce Co-Marketing Collaboration To Offer Rapid Direct-From-Blood Diagnostics And AI-Powered Decision Support Platform To Address Bloodstream Infections And Combat Antibiotic Resistance Crisis

T2 Biosystems Sees Q4 Revenue $2.5M-$3.5M Vs $3.7M Est.

T2 Biosystems Sees Preliminary Q3 Revenue $2.0M VS $2.8M Est.

T2 Biosystems Enters Multi-Year Exclusive U.S. Agreement With Cardinal Health To Sell FDA-Cleared Direct-From-Blood Diagnostics For Rapid Sepsis Detection, Including T2Dx Instrument, T2Bacteria Panel, And T2Candida Panel

T2 Biosystems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today highlighted a recently published article in The Lancet, a world-leading medical journal. The article titled "Changing the Culture of Blood Culture" was authored by Sally&nbsp;Davies,&nbsp;Richard A&nbsp;Marfuggi,&nbsp;Rick A&nbsp;Bright,&nbsp;Steve&nbsp;Brozak, and&nbsp;Michael&nbsp;Osterholm on September 20, 2024.

T2 Biosystems Highlights New Article Published In The Lancet, Titled "Changing The Culture Of Blood Culture"

T2 Biosystems Successfully Defends Patent For Direct-From-Whole Blood Pathogen Detection Method In European Union, Maintaining Strong IP Position

T2 Biosystems Receives FDA Clearance To Market T2Candida Panel For Pediatric Patients, The Only Test Detecting Sepsis-Causing Candida Species Directly From Blood In 3-5 Hours Without Blood Culture; Panel Detects Five Candida Species Responsible For 95% Of U.S. Bloodstream Infections

<ul>
<li>Finalizing a 510(k) premarket notification application for the T2Resistance&#xAE; Panel planned to be filed with the U.S. Food and Drug Administration (FDA) during the fourth quarter of 2024.</li>
<li>The previously submitted 510(k) premarket notification to expand use of the T2Candida&#xAE; Panel to detect pediatric Candida infections is pending clearance with the FDA.</li>
<li>Advanced internal validation and plans to submit a 510(k) premarket notification to the FDA to expand the use of its FDA-cleared T2Bacteria&#xAE; Panel to detect pediatric bacterial infections.</li>
<li>The Company maintains its plan to launch the T2Lyme&#x2122; Panel as a Laboratory Developed Test (LDT); however, it now plans to build or buy its own laboratory rather than launch through a partnership.
<ul>
<li>Pursuing non-dilutive funding to complete the development, validation, and clinical studies for a diagnostic test to detect Candida auris, following the completion of feasibility and early development in collaboration with the U.S. Centers for Disease Control and Prevention (CDC).</li>
</ul>
</li>
</ul>

T2 Biosystems Provides Updates On New Product Development Pipeline Progress

<a href="https://www.tga.gov.au/resources/artg/459987" title="https://www.tga.gov.au/resources/artg/459987">https://www.tga.gov.au/resources/artg/459987</a>

Global

T2 Biosystems  Gets Australian Approval For Its T2Candida In Vitro Diagnostic For The Detection Of Sepsis-Causing Fungal Pathogens From Whole Blood

T2 Biosystems shares are trading higher after the company reported better-than-expected Q2 EPS results. Also, Canaccord Genuity maintained a Hold rating on the stock and raised its price target from $3 to $5.

Health Care

Press Releases

T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens

T2 Biosystems, Inc. and Prxcision, Inc. Announce Co-Marketing Collaboration for Rapid Direct-From-Blood Diagnostics and AI-Powered Decision Support Platform

T2 Biosystems to Host Business Update Call on October 10, 2024

T2 Biosystems to Report Third Quarter 2024 Financial Results and Business Updates on November 14, 2024

T2 Biosystems Announces Third Quarter 2024 Financial Results

T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens

T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.

T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally

T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor

T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

Canaccord Genuity

Alliance Global Partners

Comments

T2 Biosystems

T2 Biosystems (TTOO) 옵션

Loading...

뉴스

파트너 / 기고자

벤징가 글로벌